MedPath

Diphenhydramine

Generic Name
Diphenhydramine
Brand Names
Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
58-73-1
Unique Ingredient Identifier
8GTS82S83M
Background

Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system . While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use .

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system .

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Indication

Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea .

Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:

i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated ;

ii) the active treatment of motion sickness ; and

iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents .

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
Associated Therapies
Airway secretion clearance therapy, Expectorant

Diphenhydramine and Sweating

Phase 4
Completed
Conditions
Sweating
Diphenhydramine Causing Adverse Effects in Therapeutic Use
Allergic Rhinitis
Hyperthermia
Interventions
First Posted Date
2022-10-19
Last Posted Date
2023-09-13
Lead Sponsor
Lakehead University
Target Recruit Count
20
Registration Number
NCT05586477
Locations
🇨🇦

Lakehead Unviersity, Thunder Bay, Ontario, Canada

Trial of Diphenhydramine for Sleep in Children With Autism

Phase 2
Recruiting
Conditions
Autism
Autism Spectrum Disorder
Interventions
First Posted Date
2022-08-15
Last Posted Date
2025-03-04
Lead Sponsor
Stanford University
Target Recruit Count
26
Registration Number
NCT05501678
Locations
🇺🇸

Stanford University, Stanford, California, United States

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

First Posted Date
2022-06-06
Last Posted Date
2024-11-14
Lead Sponsor
Sanofi
Target Recruit Count
531
Registration Number
NCT05405166
Locations
🇺🇸

Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States

🇺🇸

Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States

🇺🇸

Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States

and more 143 locations

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Phase 1
Completed
Conditions
Asymptomatic Hyperuricemia
Interventions
First Posted Date
2022-03-31
Last Posted Date
2023-12-27
Lead Sponsor
Shanghai Institute Of Biological Products
Target Recruit Count
45
Registration Number
NCT05302388
Locations
🇨🇳

The first affiliated hospital of Bengbu medical college, Bengbu, Anhui, China

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2
Not yet recruiting
Conditions
Neoplasms, Plasma Cell
Paraproteinemias
Multiple Myeloma
Neoplasms by Histologic Type
Blood Protein Disorders
Hematologic Diseases
Renal Impairment
Neoplasms
Interventions
First Posted Date
2022-03-28
Last Posted Date
2022-03-28
Lead Sponsor
Hellenic Society of Hematology
Target Recruit Count
108
Registration Number
NCT05298683
Locations
🇬🇷

General Hospital of Athens "Evangelismos", Athens, Greece

🇬🇷

Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece

🇬🇷

General Hospital of Athens "Alexandra", Athens, Greece

and more 3 locations

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

First Posted Date
2022-03-18
Last Posted Date
2025-05-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
42
Registration Number
NCT05285813
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Phase 3
Recruiting
Conditions
Cannabis Hyperemesis Syndrome
Interventions
First Posted Date
2022-02-17
Last Posted Date
2023-01-20
Lead Sponsor
Mercy Health Ohio
Target Recruit Count
45
Registration Number
NCT05244460
Locations
🇺🇸

Mercy Health - Austintown, Austintown, Ohio, United States

🇺🇸

St. Joseph-Warren Hospital, Warren, Ohio, United States

🇺🇸

St Elizabeth Youngstown Hospital, Youngstown, Ohio, United States

and more 1 locations

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Phase 3
Active, not recruiting
Conditions
Relapsing Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Interventions
First Posted Date
2022-02-10
Last Posted Date
2025-05-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
236
Registration Number
NCT05232825
Locations
🇮🇹

IRCCS Istituto Neurologico Neuromed, Pozzilli, Molise, Italy

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇨🇿

Fakultni nemocnice u sv. Anny, Brno, Czechia

and more 34 locations

Central Nervous System Effects Following Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling

Phase 4
Terminated
Conditions
Central Nervous System Effects of Diphenhydramine
Pharmacokinetics of Diphenhydramine
First Posted Date
2022-02-02
Last Posted Date
2024-02-14
Lead Sponsor
Dent Neuroscience Research Center
Target Recruit Count
3
Registration Number
NCT05219604
Locations
🇺🇸

Dent Neurologic Institute, Amherst, New York, United States

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Phase 1
Active, not recruiting
Conditions
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
Interventions
Other: Peg-filgrastim
Diagnostic Test: CT Scan (chest, abdomen, and pelvis)
Diagnostic Test: MRI
Diagnostic Test: 18f-FDG-PET
Diagnostic Test: PET
Diagnostic Test: Lumbar puncture/Ommaya tap
Diagnostic Test: Bone marrow aspiration/biopsy
Combination Product: EKG
First Posted Date
2022-01-27
Last Posted Date
2025-04-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
14
Registration Number
NCT05211336
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath